We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Thought Field Therapy and Cognitive Therapy for Agoraphobia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00932919
Recruitment Status : Completed
First Posted : July 7, 2009
Last Update Posted : April 23, 2014
Information provided by (Responsible Party):
Sorlandet Hospital HF

Brief Summary:
The purpose for this study is to find out if Thought field therapy has the same effect as, or better effect than, Cognitive therapy for Agoraphobia.

Condition or disease Intervention/treatment
Agoraphobia Behavioral: Thought field therapy Behavioral: Cognitive therapy Behavioral: Wait list

Detailed Description:

Thought field therapy is an alternative treatment method that has shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 72 patients will be randomized to three groups. 24 patients will receive cognitive therapy as a control method, 24 patients will receive thought field therapy. The remaining 24 patients will wait three months, and then be randomized to either of the two therapies.

Before inclusion all patients will be diagnosed with M.I.N.I. and SCID II. They will fill out self evaluation forms for symptoms and quality of life, before and after treatment, and one year after treatment.

All patients will undergo an interview with ADIS on panic and agoraphobic diagnosis and symptoms before starting treatment, and on panic and agoraphobic symptoms immediately after and one year after treatment. These interviews will be done by psychologists who are blinded for which type of treatment the patients have got.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy
Study Start Date : October 2006
Primary Completion Date : November 2010
Study Completion Date : November 2010

Arm Intervention/treatment
Experimental: Thought field therapy
24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
Behavioral: Thought field therapy
5 sessions with Thought field therapy
Other Name: TFT
Active Comparator: Cognitive therapy
Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
Behavioral: Cognitive therapy
12 sessions of Cognitive therapy
Other Name: CBT
Wait list
24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
Behavioral: Wait list
3 months waiting, then randomized to either thought field therapy or cognitive therapy
Other Name: WL

Primary Outcome Measures :
  1. Change in agoraphobic situation scores in ADIS. [ Time Frame: Immedeately and 12 months after treatment ]

Secondary Outcome Measures :
  1. Interference score in ADIS [ Time Frame: Immediately and 12 months after treatment ]
  2. Mobility Inventory [ Time Frame: Immediately and 12 months after treatment ]
  3. Agoraphobic Cognitions Questionnaire [ Time Frame: Immediately and 12 months after treatment ]
  4. Body Sensations Questionnaire [ Time Frame: Immediately and 12 months after treatment ]
  5. BDI [ Time Frame: Immediately and 12 months after treatment ]
  6. BAI [ Time Frame: Immediately and 12 months after treatment ]
  7. WHOQOL-BREF [ Time Frame: Immediately and 12 months after treatment ]
  8. SF-36 [ Time Frame: Immediately and 12 months after treatment ]
  9. Safety Seeking Behaviours Questionnaire. [ Time Frame: Immediately and 12 months after treatment ]
  10. Panic scale [ Time Frame: Immediately and 12 months after treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ages 18 years or older,
  • Patients with agoraphobia,
  • Patients with a score on Mobility Inventory "Alone" of 2.5 or more,
  • Patients who give a written consent to participate.

Exclusion Criteria:

  • Psychosis (past or present),
  • Drug abuse or dependency,
  • Moderate or high score on suicidal behaviour on the M.I.N.I.,
  • Patients who have another illness (other than panic disorder or agoraphobia) and are in need of immediate treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00932919

Sorlandet Hospital
Arendal, Norway, 4809
Sponsors and Collaborators
Sorlandet Hospital HF
Principal Investigator: Audun C Irgens, MD Sorlandet Hospital HF, Norway

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sorlandet Hospital HF
ClinicalTrials.gov Identifier: NCT00932919     History of Changes
Other Study ID Numbers: SSHF-70343-AUIR-2
First Posted: July 7, 2009    Key Record Dates
Last Update Posted: April 23, 2014
Last Verified: April 2014

Keywords provided by Sorlandet Hospital HF:
Cognitive therapy
Thought field therapy
Psychotherapy research

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders